KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals (REGN) has disclosed Operating Leases for 4 consecutive years, with $986.8 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Leases rose 3.39% year-over-year to $986.8 million; the TTM value through Dec 2025 reached $986.8 million, up 3.39%, while the annual FY2025 figure was $986.8 million, 3.39% up from the prior year.
  • Operating Leases hit $986.8 million in Q4 2025 for Regeneron Pharmaceuticals, up from $954.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $986.8 million in Q4 2025 and bottomed at $788.2 million in Q4 2022.
  • Average Operating Leases over 4 years is $884.3 million, with a median of $881.0 million recorded in 2023.
  • Year-over-year, Operating Leases increased 2.47% in 2023 and then increased 18.16% in 2024.
  • Regeneron Pharmaceuticals' Operating Leases stood at $788.2 million in 2022, then rose by 2.47% to $807.7 million in 2023, then rose by 18.16% to $954.4 million in 2024, then grew by 3.39% to $986.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $986.8 million, $954.4 million, and $807.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.